List of Excipients in Branded Drug IBUPROFEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lupin Pharmaceuticals Inc	IBUPROFEN AND FAMOTIDINE	ibuprofen and famotidine	70748-312	CELLULOSE, MICROCRYSTALLINE
Lupin Pharmaceuticals Inc	IBUPROFEN AND FAMOTIDINE	ibuprofen and famotidine	70748-312	CROSCARMELLOSE SODIUM
Lupin Pharmaceuticals Inc	IBUPROFEN AND FAMOTIDINE	ibuprofen and famotidine	70748-312	FD&C BLUE NO. 1
Lupin Pharmaceuticals Inc	IBUPROFEN AND FAMOTIDINE	ibuprofen and famotidine	70748-312	FD&C BLUE NO. 2--ALUMINUM LAKE

Generic Drugs Containing IBUPROFEN

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	ibuprofen	0121-0918	ACESULFAME POTASSIUM
Pharmaceutical Associates Inc	ibuprofen	0121-0918	ANHYDROUS CITRIC ACID
Pharmaceutical Associates Inc	ibuprofen	0121-0918	GLYCERIN
Pharmaceutical Associates Inc	ibuprofen	0121-0918	POLYSORBATE 80

What are the Most Frequently-Used Excipients in IBUPROFEN?

# Of NDCs	Excipient
6	1,4-SORBITAN
52	ACESULFAME POTASSIUM
11	ALUMINUM OXIDE
31	AMMONIA

Ibuprofen Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Ibuprofen is a mature, low-cost NSAID with limited active-ingredient patent protection and substantial formulation competition. Commercial value now depends on dissolution performance, patient convenience, taste, dosage flexibility, stability, and manufacturing efficiency rather than on basic ibuprofen tablets.

The strongest excipient opportunities are systems that improve the drug's low aqueous solubility, accelerate onset, mask bitterness, enable pediatric or geriatric dosing, reduce gastrointestinal exposure through local delivery, or support differentiated combination products.

What pharmaceutical properties determine ibuprofen excipient selection?

Ibuprofen is a weak acid with low water solubility in its neutral form. Its formulation profile creates a clear need for excipients that improve wetting, dispersion, dissolution, dose uniformity, palatability, and physical stability.

Property	Commercial formulation implication
Active ingredient	Racemic ibuprofen, commonly used as the free acid
Therapeutic class	Nonsteroidal anti-inflammatory drug
Primary indications	Pain, fever, inflammation, dysmenorrhea, arthritis
Molecular weight	About 206.28 g/mol
pKa	Approximately 4.4
Aqueous solubility	Low in acidic and neutral media; higher at alkaline pH
Biopharmaceutics	Commonly treated as a poorly soluble, highly permeable compound
Dose range	Typically 200 to 800 mg per oral dose, depending on product and indication
Main formulation risks	Slow dissolution, gastric irritation, taste, sedimentation, sticking, and oxidation-related degradation
Regulatory status	Long-established prescription and OTC active ingredient

Ibuprofen's weak-acid behavior makes pH adjustment, salt formation, surfactants, particle engineering, and lipid-based systems relevant. The free acid can dissolve more readily at higher pH, but alkaline systems can create taste, tolerability, packaging, and stability challenges.

Which excipients are most important for ibuprofen formulations?

Solubilizers and wetting agents

Surfactants can improve powder wetting and increase the effective surface area available for dissolution. Common candidates include polysorbates, sodium lauryl sulfate, poloxamers, and selected pharmacopeial surfactants.

These materials are most useful in:

• Immediate-release tablets
• Oral suspensions
• Softgels
• Liquid-filled capsules
• Fast-dissolving granules
• Amorphous or lipid-based systems

Surfactant selection requires control of foaming, peroxide content, capsule compatibility, taste, and gastrointestinal tolerance. Excessive surfactant loading can create manufacturing and sensory problems without producing a proportional dissolution benefit.

Alkalinizing agents and buffers

Sodium bicarbonate, sodium carbonate, citrate systems, phosphates, and other buffering agents can increase ibuprofen ionization and improve dissolution. The approach is commercially attractive for rapid-onset products but requires careful control of microenvironmental pH.

Key risks include:

• Chemical instability in aqueous products
• Strong or alkaline taste
• Gas generation in effervescent systems
• Capsule-shell interaction
• Increased osmolality in liquids
• Potential changes in gastric tolerability

Buffer systems are most defensible when they support a measurable clinical or consumer benefit, such as faster dissolution or shorter time to analgesic effect.

Binders, disintegrants, and compression aids

Conventional immediate-release ibuprofen tablets require a balance between mechanical strength and rapid disintegration. Suitable excipient classes include:

• Microcrystalline cellulose
• Pregelatinized starch
• Povidone
• Croscarmellose sodium
• Sodium starch glycolate
• Crospovidone
• Mannitol
• Dibasic calcium phosphate
• Colloidal silicon dioxide
• Magnesium stearate

Ibuprofen is hydrophobic and can be difficult to granulate or compress consistently. Over-lubrication with magnesium stearate may reduce tablet wettability and slow dissolution. High-dose tablets also create a size problem, making direct compression, dry granulation, multilayer tablets, or higher-drug-load excipient systems commercially relevant.

Suspending and viscosity agents

Liquid ibuprofen products need physical stability, redispersibility, dose uniformity, and acceptable mouthfeel. Common suspending or thickening systems include:

• Xanthan gum
• Microcrystalline cellulose and carboxymethylcellulose combinations
• Hydroxyethylcellulose
• Hypromellose
• Carbomers
• Sodium carboxymethylcellulose

The preferred system must keep particles suspended during storage but remain pourable and easy to redisperse. Excessive viscosity can reduce dosing accuracy and create residual product loss in the bottle.

Sweeteners, flavors, and taste-masking agents

Ibuprofen has a strong, unpleasant taste that is particularly important in pediatric products. High-value taste-masking strategies include:

• Sucrose or sorbitol syrups
• Sucralose, saccharin, or acesulfame potassium
• Flavors such as berry, orange, or grape
• Polymer coatings
• Ion-exchange resins
• Lipid encapsulation
• Complexation systems
• Multiparticulates or coated granules

Taste masking is more difficult at higher drug loading and in products that release ibuprofen rapidly in the mouth. Resin complexes and polymer coatings can create differentiated pediatric products, but the release profile must remain equivalent to the intended immediate-release product.

What formulations are protected or differentiated by excipient strategy?

Ibuprofen formulation competition is concentrated in six commercial platforms.

Platform	Key excipient objective	Commercial opportunity
Conventional tablet	Compression, disintegration, dissolution	Low-cost generic and private-label supply
Film-coated tablet	Swallowability, taste, moisture protection	Branded OTC and pharmacy products
Softgel	Solubilization and rapid release	Premium pain-relief positioning
Oral suspension	Sedimentation control, taste masking	Pediatric and geriatric markets
Chewable tablet	Taste masking and rapid disintegration	Pediatric and convenience products
Topical gel or cream	Solubilization, skin penetration, sensory profile	Local pain and inflammation products

Softgel and liquid-filled capsule systems

Softgels can use polyethylene glycol, propylene glycol, glycerol, medium-chain triglycerides, surfactants, and co-solvents to keep ibuprofen dispersed or partially solubilized. The main commercial advantages are:

• Faster apparent dissolution
• Smooth swallowing
• Premium presentation
• Reduced tablet disintegration variability
• Differentiation from standard generics

The main technical barriers are shell compatibility, fill viscosity, precipitation during storage, migration, oxygen sensitivity, and scale-up. Liquid-filled systems require careful control of ibuprofen concentration because the formulation can become supersaturated after shell rupture or dilution in gastrointestinal fluid.

Pediatric suspensions and chewables

Pediatric products offer the clearest excipient-led differentiation. The formulation must deliver accurate low-volume dosing, palatable taste, stable suspension behavior, and resistance to microbial growth.

Commercial opportunities include:

• Higher-concentration suspensions that reduce dosing volume
• Dye-free and sugar-free products
• Allergen-conscious formulations
• Improved syringe dosing
• Longer in-use stability
• Taste-masked chewables
• Unit-dose sachets or stick packs

Preservatives, sweeteners, and viscosity modifiers must be assessed together. A preservative system that is effective in a low-pH vehicle may not perform equivalently after pH adjustment for ibuprofen solubility.

Topical ibuprofen products

Topical products depend on penetration enhancers, solvents, emulsifiers, gelling agents, and skin-compatible preservatives. Candidate systems may include carbomer gels, hydroalcoholic vehicles, propylene glycol, diethylene glycol monoethyl ether, isopropyl alcohol, phospholipids, and emulsion systems.

Commercial differentiation can focus on:

• Non-greasy sensory performance
• Fast drying
• Reduced odor
• Improved skin penetration
• Lower transfer to clothing
• Larger multidose packages
• Local delivery for musculoskeletal pain

Topical ibuprofen products face a more complex development pathway than conventional oral generics because drug release, skin permeation, local tolerability, and clinical performance can all affect regulatory acceptance.

How does ibuprofen compare with other NSAID excipient opportunities?

Ibuprofen has a more mature and competitive formulation market than many newer analgesics. Its low cost limits the value of minor improvements, but its favorable safety familiarity and broad consumer use support premium delivery formats.

Attribute	Ibuprofen	Naproxen	Diclofenac
Common oral dose burden	Moderate to high	Moderate	Lower in some dosage forms
Taste-masking need	High in pediatric liquids	High	Relevant but less dominant
Solubility challenge	Significant for free acid	Significant	Significant
Softgel opportunity	Strong	Strong	Moderate
Pediatric OTC opportunity	Strong	More limited	Limited in some markets
Topical opportunity	Strong	Moderate	Strong
Mature generic competition	Very high	High	High
Excipient-led premium potential	Moderate	Moderate	Moderate to strong

Ibuprofen's dose size makes compact tablets and high-load formulations more difficult than products with lower milligram requirements. Its large pediatric and OTC base creates more opportunities for liquids, chewables, softgels, and combination products.

What patent and exclusivity protections affect ibuprofen formulations?

Ibuprofen has no meaningful remaining new-chemical-entity exclusivity in the United States. The active ingredient has been marketed for decades, and conventional oral ibuprofen products are exposed to extensive generic competition.

Protection category	Ibuprofen position
NCE exclusivity	Expired
Basic active-ingredient patent protection	Expired
Pediatric exclusivity	Product-specific and historical; no general current protection for ibuprofen
Orange Book patent protection	Product-specific; conventional ibuprofen products generally do not depend on a single dominant active-ingredient patent
Formulation patents	May exist for specific products, delivery systems, salts, release profiles, or excipient combinations
Method-of-use patents	Potentially relevant for narrow indications or dosing regimens, but not a broad barrier to routine ibuprofen use
Biosimilar exposure	Not applicable; ibuprofen is a small molecule
ANDA competition	Extensive for standard oral dosage forms

A formulation patent can protect a particular composition, manufacturing process, particle size, release profile, or delivery platform. It does not automatically block a generic product using a different excipient system.

Patent value is highest when the claim covers a product attribute that is difficult to design around, such as:

• A specific solubilized ibuprofen system
• A defined particle-size distribution
• A coated multiparticulate with controlled release
• A stable high-concentration suspension
• A topical penetration system
• A taste-masked pediatric composition
• A combination product with a clinically relevant release profile

Patent term for any particular ibuprofen formulation must be reviewed from the relevant filing date, patent-term adjustment, terminal disclaimers, foreign counterparts, and regulatory listing. No single patent number or expiration date accurately describes the entire ibuprofen market.

What is the Orange Book and FDA regulatory status of ibuprofen?

FDA-approved prescription ibuprofen products include tablets, capsules, and oral suspension products. OTC products are marketed under the FDA's OTC monograph framework and under approved applications, depending on the product and jurisdictional pathway. The FDA's Inactive Ingredient Database is the primary reference for precedent excipient use in approved dosage forms and routes.[1][2]

For generic development, the principal regulatory issues are:

• Pharmaceutical equivalence
• Bioequivalence
• Dissolution performance
• Dosage-form-specific inactive ingredient precedent
• Product labeling
• Container-closure compatibility
• Microbial quality for liquids
• Stability and preservative effectiveness
• In vitro release for topical products

An excipient used in an approved oral tablet is not automatically acceptable at the same concentration in a pediatric suspension, topical gel, or softgel. Route, dosage form, maximum daily exposure, age group, and local tolerability determine regulatory risk.

What generic entry risks exist for ibuprofen products?

Generic entry risk is high for standard 200 mg and 400 mg immediate-release tablets and capsules. Manufacturers can compete through low-cost direct compression, conventional wet granulation, or dry granulation.

Risk is lower for products with technical complexity, including:

• High-concentration pediatric suspensions
• Stable liquid-filled capsules
• Multiparticulate taste-masked products
• Topical products requiring demonstrated skin delivery
• Modified-release systems
• Combination products
• Products with proprietary packaging or dosing devices

The commercial defense for an ibuprofen brand is usually product performance and channel positioning rather than broad patent exclusion. A premium product needs evidence of meaningful differentiation, such as faster onset, smaller dose volume, improved taste, easier swallowing, longer stability, or better consumer adherence.

Which companies are positioned in the ibuprofen market?

The market includes originator brands, private-label retailers, generic pharmaceutical companies, contract manufacturers, and excipient suppliers.

Relevant commercial groups include:

• Kenvue, through Advil-branded products
• Perrigo, through private-label and consumer-health manufacturing
• Haleon, through pain-relief and combination brands in selected markets
• Large generic manufacturers supplying prescription and OTC channels
• Contract development and manufacturing organizations
• Excipient suppliers such as BASF, Roquette, DFE Pharma, Evonik, Lubrizol, Ashland, and Kerry

The most attractive partnership opportunities are not basic ibuprofen tablet supply agreements. They are platform deals involving:

• Ready-to-use direct-compression blends
• Taste-masking technology
• Softgel fill systems
• Pediatric suspension platforms
• Topical delivery systems
• Continuous manufacturing
• High-throughput coating
• Stable preservative systems
• Low-sugar or sugar-free vehicles

What manufacturing and intellectual-property barriers matter most?

The strongest manufacturing barriers are process-control barriers rather than raw-material scarcity.

High-dose tablet manufacturing

Ibuprofen's dose size increases tablet weight and can cause:

• Poor flow
• Capping or lamination
• Sticking to punches
• Slow disintegration
• Content-uniformity risk in low-dose combination products
• Reduced throughput

Particle engineering, granulation control, lubricant management, and compression tooling are central to commercial performance.

Liquid and suspension manufacturing

Suspensions require control of particle size, wetting, viscosity, density matching, sedimentation, and redispersion. Scale-up can alter shear history and particle-particle interactions, causing a product that passes laboratory testing to fail at commercial scale.

Softgel manufacturing

Softgel systems create IP opportunities but also demand control of fill-shell interaction, water migration, oxygen exposure, and precipitation. A stable formulation that remains homogeneous over shelf life is more valuable than a formulation that only produces rapid initial dissolution.

Topical manufacturing

Topical products require consistent drug distribution, rheology, emulsion stability, microbial control, and packaging compatibility. Pumps, tubes, and airless containers can become part of the product's commercial and regulatory differentiation.

What licensing and commercial opportunities exist for ibuprofen excipients?

Licensing opportunities are concentrated in formulation platforms with transferable value across multiple NSAIDs. A successful ibuprofen platform can often be extended to naproxen, ketoprofen, diclofenac, or other poorly soluble acidic drugs, subject to performance and regulatory constraints.

The most attractive deal structures include:

1. Royalty-bearing licenses for taste-masked ibuprofen particles.
2. Supply agreements for pre-engineered direct-compression excipient blends.
3. Co-development agreements for fast-dissolving softgel fills.
4. Regional rights for pediatric liquid formulations.
5. Contract manufacturing agreements for topical gels.
6. Platform licenses covering particle coating, amorphous dispersion, or lipid delivery.
7. Private-label partnerships using differentiated packaging and dosing devices.

A formulation company should protect the full product architecture where possible: composition, process, particle attributes, packaging, and use. A narrow excipient-only claim may be easier to design around than a claim tied to measurable dissolution, stability, taste, or delivery performance.

How strong is the ibuprofen patent estate?

The broad ibuprofen patent estate is weak because the active ingredient and conventional dosage forms are old. Specific formulation estates can still be commercially useful when they cover a difficult technical problem and have enforceable claims.

Estate type	Relative strength	Reason
Conventional immediate-release tablet	Low	Many established excipient alternatives
Standard oral suspension	Low to moderate	Formulation design-around is usually possible
Pediatric taste-masked product	Moderate	Sensory performance and particle coating may be difficult to replicate
Liquid-filled softgel	Moderate	Fill composition and shell compatibility can create technical barriers
Topical delivery system	Moderate	Skin delivery and composition claims may be narrower but more specialized
Modified-release product	Moderate to high	Release profile and clinical performance can increase complexity
Combination product	Product-specific	Strength depends on ingredients, indication, and claim scope
Manufacturing process	Moderate	Stronger when process controls produce defined critical quality attributes

What are the best commercial opportunities for ibuprofen excipients?

The highest-potential areas are:

• Sugar-free pediatric suspensions
• High-concentration liquids that reduce dosing volume
• Fast-dissolving softgels
• Taste-masked chewables
• Topical gels with improved sensory properties
• Ready-to-use compression systems for high-dose tablets
• Combination analgesics with controlled release
• Unit-dose and travel-friendly packaging
• Products designed for older adults with swallowing difficulty
• Low-irritancy, alcohol-free topical systems

Basic excipient substitution is unlikely to support durable pricing. A commercially viable product should connect the excipient choice to a measurable product claim, such as faster dissolution, improved redispersion, reduced volume, longer stability, better taste, or improved application experience.

Key Takeaways

• Ibuprofen is a highly commoditized active ingredient with expired core exclusivity and extensive generic competition.
• Excipient value is concentrated in dissolution enhancement, taste masking, suspension stability, softgel performance, and topical delivery.
• Pediatric liquids, chewables, softgels, and topical gels offer stronger differentiation than standard tablets.
• FDA inactive-ingredient precedent, dosage-form compatibility, and exposure limits are central to regulatory strategy.
• Conventional ibuprofen tablets carry high generic-entry risk and limited patent defensibility.
• Formulation patents are strongest when they cover a difficult technical result, not merely a broad list of conventional excipients.
• Licensing opportunities are most attractive for platforms that can extend beyond ibuprofen to other poorly soluble NSAIDs.
• Commercial success requires a measurable consumer or manufacturing advantage supported by stable, scalable formulation performance.

FAQs About Ibuprofen Excipient Strategy

Can ibuprofen be formulated without surfactants?

Yes. Conventional tablets can use granulation, particle-size control, disintegrants, and wetting optimization without surfactants. Surfactants become more useful when rapid dissolution, liquid delivery, softgels, or high-concentration systems are required.

Which excipient is best for masking ibuprofen taste?

No single excipient is universally best. Polymer coating, ion-exchange resin complexation, lipid encapsulation, and intense sweetener-flavor systems are the leading approaches. The best choice depends on drug loading, release requirements, dosage form, and target age group.

Are ibuprofen salts commercially superior to free ibuprofen?

Ibuprofen salts can improve aqueous solubility and dissolution, but they may introduce differences in dose equivalence, hygroscopicity, taste, stability, and regulatory treatment. The commercial advantage must be demonstrated through product performance rather than assumed from salt formation alone.

Can excipients reduce ibuprofen gastrointestinal risk?

Excipients can alter dissolution, local concentration, and delivery route, but they do not eliminate the systemic and gastrointestinal risks associated with NSAIDs. Topical delivery may reduce systemic exposure in some products, but performance depends on formulation and clinical evidence.

Is a new ibuprofen excipient combination likely to receive patent protection?

It may receive protection if it provides a novel, non-obvious composition or process with defined technical advantages. A routine substitution of one conventional binder, sweetener, or disintegrant for another is less likely to support strong patent claims.

References

1. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
3. U.S. Food and Drug Administration. (2024). Electronic Code of Federal Regulations, 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention.
5. Davies, N. M. (1998). Clinical pharmacokinetics of ibuprofen: The first 30 years. Clinical Pharmacokinetics, 34(2), 101-154.
6. British Pharmacopoeia Commission. (2024). British Pharmacopoeia 2024. London, United Kingdom: The Stationery Office.